Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RXYLT1 antisense RNA 1 (RXYLT1-AS1) is a long non-coding RNA (lncRNA) gene located on chromosome 12 and is transcribed as an RNA molecule but not translated into protein. It is also annotated as TMEM5 antisense RNA 1, reflecting its partial overlap or antisense relationship with the TMEM5 gene. There is currently limited functional characterization of RXYLT1-AS1, but as a member of the antisense lncRNA class, similar molecules are known to regulate the expression of protein-coding genes through mechanisms such as cis- or trans-modulation of their corresponding sense transcripts. RXYLT1-AS1 is associated in genetic databases with lissencephaly, but its direct role in disease or therapeutic targeting is not established. Current evidence places RXYLT1-AS1 in the "Other" category for molecular classification due to its nature as a lncRNA and lack of evidence classifying it under common druggable target families such as receptors, enzymes, or ion channels. No therapeutically relevant drugs, clinical mechanisms of action, or safety issues are described for this molecule. It is not a protein-coding gene, receptor, or established therapeutic target.
null
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RXYLT1 antisense RNA 1 (RXYLT1-AS1).